These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 1567178)
1. In vitro modulating effect of the reversible protein synthesis inhibitor zilascorb (2H) on cis-diamminedichloroplatinum (II)-induced cytotoxicity. Melvik JE; Dornish JM; Larsen RO; Børretzen B; Oftebro R; Pettersen EO Anticancer Res; 1992; 12(1):33-8. PubMed ID: 1567178 [TBL] [Abstract][Full Text] [Related]
2. Effect on protein synthesis and cell survival of the benzaldehyde derivatives sodium benzylidene ascorbate (SBA) and the deuterated compound zilascorb(2H). Pettersen EO; Larsen RO; Boerretzen B; Dornish JM; Oftebro R Anticancer Res; 1991; 11(3):1077-81. PubMed ID: 1888141 [TBL] [Abstract][Full Text] [Related]
3. Tumour necrotisation in nude mice xenografts by the reversible protein synthesis inhibitor zilascorb(2H). Pettersen EO; Larsen RO; Dornish JM; Børretzen B; Juul ME; Aastveit TE; Nesland JM; Rofstad EK; Oftebro R Br J Cancer; 1993 Apr; 67(4):650-6. PubMed ID: 8471421 [TBL] [Abstract][Full Text] [Related]
4. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity. Vadi H; Drewinko B Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232 [TBL] [Abstract][Full Text] [Related]
5. 1-beta-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diamminedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Swinnen LJ; Barnes DM; Fisher SG; Albain KS; Fisher RI; Erickson LC Cancer Res; 1989 Mar; 49(6):1383-9. PubMed ID: 2924295 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of cis-dichlorodiammineplatinum (II)-induced cytotoxicity by methylglyoxal. Dornish JM; Pettersen EO Anticancer Res; 1989; 9(4):1137-42. PubMed ID: 2817795 [TBL] [Abstract][Full Text] [Related]
7. Oxygen- and temperature-dependent cytotoxic and radiosensitizing effects of cis-dichlorodiammineplatinum(II) on human NHIK 3025 cells in vitro. Melvik JE; Pettersen EO Radiat Res; 1988 Jun; 114(3):489-99. PubMed ID: 3375438 [TBL] [Abstract][Full Text] [Related]
8. Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents. Montine TJ; Borch RF Cancer Res; 1988 Nov; 48(21):6017-24. PubMed ID: 2458831 [TBL] [Abstract][Full Text] [Related]
9. Zilascorb(2H), a low-toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma. Semb KA; Aamdal S; Mette E; Ingvar C; Gullaksen N; Osmundsen K Anticancer Drugs; 1998 Oct; 9(9):797-802. PubMed ID: 9840726 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Ali-Osman F; Berger MS; Rajagopal S; Spence A; Livingston RB Cancer Res; 1993 Dec; 53(23):5663-8. PubMed ID: 8242621 [TBL] [Abstract][Full Text] [Related]
11. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Wallner KE; DeGregorio MW; Li GC Cancer Res; 1986 Dec; 46(12 Pt 1):6242-5. PubMed ID: 3779644 [TBL] [Abstract][Full Text] [Related]
12. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells. Fram RJ; Woda BA; Wilson JM; Robichaud N Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559 [TBL] [Abstract][Full Text] [Related]
13. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504 [TBL] [Abstract][Full Text] [Related]
14. Combination effects of cis-dichlorodiammineplatinum with selected metahalones, pyrimidine sulfoxides and pyrimidine sulfones on human NHIK 3025 cells in vitro. Dornish JM; Undheim K; Pettersen EO; Oftebro R; Laland SG Anticancer Drug Des; 1988 Dec; 3(3):191-8. PubMed ID: 3207466 [TBL] [Abstract][Full Text] [Related]
15. Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Semb KA; Fodstad O; Klem B; Bibow K; Osmundsen K; Aamdal S Anticancer Drugs; 1997 Mar; 8(3):296-303. PubMed ID: 9095337 [TBL] [Abstract][Full Text] [Related]
16. Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Sorenson CM; Eastman A Cancer Res; 1988 Dec; 48(23):6703-7. PubMed ID: 3180081 [TBL] [Abstract][Full Text] [Related]
17. Effect on cell survival and protein synthesis of benzylidene-glucose (BG) and the deuterated analogue P-1013 in cultured cells. Dunsaed CB; Dornish JM; Oftebro R; Pettersen EO Anticancer Res; 1995; 15(5B):1921-7. PubMed ID: 8572579 [TBL] [Abstract][Full Text] [Related]
18. Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Ducore JM; Erickson LC; Zwelling LA; Laurent G; Kohn KW Cancer Res; 1982 Mar; 42(3):897-902. PubMed ID: 7199380 [TBL] [Abstract][Full Text] [Related]
19. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs. Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318 [TBL] [Abstract][Full Text] [Related]
20. Reduced cellular uptake of cis-dichlorodiammine-platinum by benzaldehyde. Dornish JM; Melvik JE; Pettersen EO Anticancer Res; 1986; 6(4):583-8. PubMed ID: 3752939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]